Seven new ABCB11 gene mutations identified as cause of PFIC2
Seven new ABCB11 gene mutations were identified as the likely cause of progressive familial intrahepatic cholestasis (PFIC2), according to a study that analyzed the…
News
Dosing begins in Phase 2 trial of DD01 in treating fatty liver disease
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of two forms of fatty…
Atypical biliary tract abnormalities found in Alagille syndrome baby
A six-month-old baby with Alagille syndrome showed atypical biliary tract abnormalities, including a narrower main bile duct and a gallbladder with a corkscrew-like shape,…
Antiviral treatment combo leads to sustained HCV clearance in trial
A two-month regimen of Atea Pharmaceuticals’ once-daily oral antiviral treatment for hepatitis C — a combination of bemnifosbuvir and ruzasvir — leads to sustained…
Orsini, Pantherx pharmacies will dispense Livdelzi for PBC in US
Specialty pharmacy services for Livdelzi (seladelpar), the newly approved second-line therapy for adults with primary biliary cholangitis (PBC), will be provided in the U.S.
Liver disease in pregnancy linked to worse maternal, newborn outcomes
Intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver disease, is significantly linked to higher rates of several maternal, fetal, and newborn issues…
Efruxifermin Phase 3 trials now enrolling fatty liver disease patients
Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated…
Testing set for AX-0810 in biliary atresia, cholestatic liver diseases
AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early next year, according to developer…
Vaccine for hepatitis B may allow patients to stop antiviral therapy
Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use of standard antiviral medication six…
FDA approves seladelpar, now Livdelzi, to treat adults with PBC
Note: This story was updated Aug. 20, 2024, to correct that Livdelzi is not a first-in-class therapy for primary biliary cholangitis. The U.S. Food…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say